240 related articles for article (PubMed ID: 27574973)
1. Effect of Systemic Iron Overload and a Chelation Therapy in a Mouse Model of the Neurodegenerative Disease Hereditary Ferritinopathy.
Garringer HJ; Irimia JM; Li W; Goodwin CB; Richine B; Acton A; Chan RJ; Peacock M; Muhoberac BB; Ghetti B; Vidal R
PLoS One; 2016; 11(8):e0161341. PubMed ID: 27574973
[TBL] [Abstract][Full Text] [Related]
2. Neuropathological and biochemical investigation of Hereditary Ferritinopathy cases with ferritin light chain mutation: Prominent protein aggregation in the absence of major mitochondrial or oxidative stress.
Kurzawa-Akanbi M; Keogh M; Tsefou E; Ramsay L; Johnson M; Keers S; Wsa Ochieng L; McNair A; Singh P; Khan A; Pyle A; Hudson G; Ince PG; Attems J; Burn J; Chinnery PF; Morris CM
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):26-42. PubMed ID: 32464705
[TBL] [Abstract][Full Text] [Related]
3. Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice.
Vidal R; Miravalle L; Gao X; Barbeito AG; Baraibar MA; Hekmatyar SK; Widel M; Bansal N; Delisle MB; Ghetti B
J Neurosci; 2008 Jan; 28(1):60-7. PubMed ID: 18171923
[TBL] [Abstract][Full Text] [Related]
4. The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice.
Song D; Zhao L; Li Y; Hadziahmetovic M; Song Y; Connelly J; Spino M; Dunaief JL
Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4525-32. PubMed ID: 24970260
[TBL] [Abstract][Full Text] [Related]
5. A novel neuroferritinopathy mouse model (FTL 498InsTC) shows progressive brain iron dysregulation, morphological signs of early neurodegeneration and motor coordination deficits.
Maccarinelli F; Pagani A; Cozzi A; Codazzi F; Di Giacomo G; Capoccia S; Rapino S; Finazzi D; Politi LS; Cirulli F; Giorgio M; Cremona O; Grohovaz F; Levi S
Neurobiol Dis; 2015 Sep; 81():119-33. PubMed ID: 25447222
[TBL] [Abstract][Full Text] [Related]
6. The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.
Hadziahmetovic M; Song Y; Wolkow N; Iacovelli J; Grieco S; Lee J; Lyubarsky A; Pratico D; Connelly J; Spino M; Harris ZL; Dunaief JL
Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):959-68. PubMed ID: 21051716
[TBL] [Abstract][Full Text] [Related]
7. Cryo-EM structures and functional characterization of homo- and heteropolymers of human ferritin variants.
Irimia-Dominguez J; Sun C; Li K; Muhoberac BB; Hallinan GI; Garringer HJ; Ghetti B; Jiang W; Vidal R
Sci Rep; 2020 Nov; 10(1):20666. PubMed ID: 33244127
[TBL] [Abstract][Full Text] [Related]
8. Deferiprone as an oral iron chelator in sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
[TBL] [Abstract][Full Text] [Related]
9. Mutant L-chain ferritins that cause neuroferritinopathy alter ferritin functionality and iron permeability.
McNally JR; Mehlenbacher MR; Luscieti S; Smith GL; Reutovich AA; Maura P; Arosio P; Bou-Abdallah F
Metallomics; 2019 Oct; 11(10):1635-1647. PubMed ID: 31513212
[TBL] [Abstract][Full Text] [Related]
10. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
11. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
13. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic mechanism and modeling of neuroferritinopathy.
Cozzi A; Santambrogio P; Ripamonti M; Rovida E; Levi S
Cell Mol Life Sci; 2021 Apr; 78(7):3355-3367. PubMed ID: 33439270
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy.
Deng X; Vidal R; Englander EW
Neurosci Lett; 2010 Jul; 479(1):44-8. PubMed ID: 20478358
[TBL] [Abstract][Full Text] [Related]
16. Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice.
Sangartit W; Pakdeechote P; Kukongviriyapan V; Donpunha W; Shibahara S; Kukongviriyapan U
Vascul Pharmacol; 2016 Dec; 87():199-208. PubMed ID: 27713040
[TBL] [Abstract][Full Text] [Related]
17. Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene.
Barbeito AG; Garringer HJ; Baraibar MA; Gao X; Arredondo M; Núñez MT; Smith MA; Ghetti B; Vidal R
J Neurochem; 2009 May; 109(4):1067-78. PubMed ID: 19519778
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).
Whiteside DP; Barker IK; Conlon PD; Tesoro A; Thiessen JJ; Mehren KG; Jacobs RM; Spino M
J Avian Med Surg; 2007 Jun; 21(2):121-9. PubMed ID: 18065133
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up.
Cossu G; Abbruzzese G; Matta G; Murgia D; Melis M; Ricchi V; Galanello R; Barella S; Origa R; Balocco M; Pelosin E; Marchese R; Ruffinengo U; Forni GL
Parkinsonism Relat Disord; 2014 Jun; 20(6):651-4. PubMed ID: 24661465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
